Biomedical applications of human cathelicidin

• Autor(es): Gama, F. M. ; Silva, João P. ; Martins-Green, Manuela ; Castro, Gil ; Pedrosa, Jorge ; Appelberg, Rui
• Data: 2015
• Identificador Persistente: https://hdl.handle.net/1822/41261
• Origem: RepositóriUM - Universidade do Minho
• Tipo de Documento: Outro
• Idioma: Inglês
• Contribuidor(es): Universidade do Minho

Descrição

[Excerpt] Antimicrobial peptides (AMPs) are good candidates to treat burn wounds, a major cause of morbidity, impaired life quality and resources consumption in developed countries. Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis, represents the second world’s deadliest infectious disease, affecting around 9 million people worldwide in 2013. Of those, about 1.1 million died from the disease. The potential of cathelicin, a human AMP, in the treatment of mycobacteriosis and wound regeneration was assessed in pre-clinical trials. (...)